Shanghai Henlius Biotech Inc (Henlius), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a biopharmaceutical company, which includes research, development, production and marketing of monoclonal antibody products. It develops medicine for oncology, autoimmune and ophthalmic diseases. The company offers products such as rituximab injection for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma; trastuzumab for breast cancer, metastatic gastric cancer and metastatic breast cancer; and adalimumab injection for ankylosing spondylitis, rheumatoid arthritis, plaque psoriasis and uveitis. It also offers bevacizumab injection and serplulimab injection. The company operates research and development centers in Shanghai, China and the US. Henlius is headquartered in Shanghai, China.
Headquarters
China
Address
9Floor, Innov Tower (Capitaland Building), 1801 Hongmei Road, Shanghai, 200233
Website
www.henlius.com
Telephone
86 21 33395800
No of Employees
3,602
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2696 (HKG)
Revenue (2022)
$477.8M
91.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
29.3%
(2022 vs 2021)
Market Cap*
$1.0B
Net Profit Margin (2022)
XYZ
63.0%
(2022 vs 2021)
* As of and is in US$
Shanghai Henlius Biotech Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Rituximab Injection | Henlius |
| Adalimumab Injection | |
| Bevacizumab Injection | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In November, the company's HLX42 for Injection, the ADC product received approval from the U.S. Food and Drug Administration for the treatment of advance/metastatic solid tumors. |
| 2023 | Contracts/Agreements | In October, Hengenix Biotech entered into a collaboration with OncoHost to offer high-quality, affordable, and innovative biologic medicines for patients worldwide. |
| 2023 | Contracts/Agreements | In October, the company entered into an exclusive license agreement with Intas Pharmaceuticals for the development and commercialization in Europe and India for several indications including ES-SCLC, and specific formulation of HANSIZHUANG. |
Competitor Comparison
| Key Parameters | Shanghai Henlius Biotech Inc | Jinyao Pharmaceutical Co Ltd | Sihuan Pharmaceutical Holdings Group Ltd | BrightGene Bio-Medical Technology Co Ltd | China Pharma Holdings Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Tianjin | Beijing | Suzhou | Haikou |
| State/Province | Shanghai | Tianjin | Beijing | Jiangsu | Hainan |
| No. of Employees | 3,602 | 2,569 | 3,241 | 1,128 | 234 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wenjie Zhangi | Chief Executive Officer; Chairman | Executive Board | 2021 | 56 |
| Jun Zhu | President; Chief Financial Officer | Senior Management | 2023 | 44 |
| Huang Wei | Chief Operating Officer; Senior Vice President | Senior Management | - | - |
| Zhang Jifeng | Chief Technology Officer; Senior Vice President | Senior Management | - | - |
| Wang Yan | Secretary | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward